verteporfin (Visudyne)

Subscribe to Selected New Research on verteporfin

492 relevant articles (72 outcomes, 98 trials/studies) found for this Drug

Description: C41H42N4O8, MW 718.794; used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION

Also Known As:

Visudyne; 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester; BPD verteporfin; BPD-MA; Novartis Ophthalmics brand of verteporfin; Novartis brand of verteporfin; QLT brand of verteporfin; benzoporphyrin derivative monoacid ring A; verteporphin

Relationship Network

Drug Context: Research Results

Experts

1.	Bressler, Neil M: 18 articles (12/2007 - 01/2002)
2.	Bressler, Susan B: 12 articles (05/2006 - 10/2002)
3.	Schmidt-Erfurth, Ursula: 10 articles (01/2008 - 10/2002)
4.	Rosenfeld, Philip J: 9 articles (12/2007 - 08/2002)
5.	Slakter, Jason S: 8 articles (12/2007 - 02/2002)
6.	Reaves, Al: 8 articles (09/2005 - 10/2002)
7.	Pece, Alfredo: 7 articles (03/2007 - 08/2004)
8.	Miller, Joan W: 7 articles (09/2005 - 07/2002)
9.	Isola, Vincenzo: 6 articles (03/2007 - 08/2004)
10.	Potter, Michael J: 6 articles (09/2005 - 10/2002)

Related Diseases

1.	Choroidal Neovascularization 12/01/2007 - "Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study." 05/01/2001 - "Other secondary outcomes, including visual acuity letter score worse than 34 (approximate Snellen equivalent of 20/200 or worse), mean change in visual acuity letter score, development of classic choroidal neovascularization, progression of classic choroidal neovascularization and size of lesion, favored the verteporfin-treated group at both the month 12 and month 24 examination for both the entire study group and the subgroup of cases with occult with no classic choroidal neovascularization at baseline" 07/01/2007 - "More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions" 01/01/2006 - "METHODS: Nineteen consecutive patients with predominantly classic choroidal neovascularization (CNV) in AMD were treated with 6 mg/m2 verteporfin given as bolus infusion" 12/01/2005 - "PURPOSE: To evaluate the time course and morphologic features of verteporfin therapy-induced vascular effects using 3-dimensional topographic angiography (TAG) in patients with choroidal neovascularization (CNV)" Get all the results and reference details, order at left...
2.	Macular Degeneration (Age-Related Maculopathy) 08/01/2004 - "The Verteporfin in Age-related Macular Degeneration (VAM) Study was designed to provide expanded access to verteporfin therapy after beneficial results for these cases were reported but before regulatory approval in North America" 07/01/2008 - "The photosensitizer verteporfin is approved for the therapy of neovascularizations, such as age-related maculopathy" 01/01/2008 - "Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration." 12/01/2007 - "Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration." 11/01/2006 - "Verteporfin therapy for neovascular age-related macular degeneration in Indian eyes." Get all the results and reference details, order at left...
3.	Hemangioma (Angioma) 09/01/2005 - "Verteporfin therapy for choroidal hemangioma: a long-term follow-up." 10/01/2003 - "CONCLUSION: Verteporfin therapy may be useful in diffuse choroidal hemangiomas." 11/01/2003 - "CONCLUSION: The present series demonstrates that even limited, low-irradiance, single-spot photodynamic therapy with verteporfin is an effective first-line treatment for choroidal hemangiomas." 11/01/2001 - "CONCLUSION: Photodynamic therapy with verteporfin is effective in eliminating subretinal fluid and improving vision in patients with circumscribed choroidal hemangioma." 03/01/2005 - "THERAPY AND OUTCOME: The hemangioma was treated with verteporphin photodynamic therapy" Get all the results and reference details, order at left...
4.	Neoplasms (Cancer) 03/15/2005 - "RESULTS: Fluorescence microscopic studies indicated that tumor localization of verteporfin changed from predominantly within the tumor vasculature at 15 min after injection, to being throughout the tumor parenchyma at 3 h after injection" 04/01/2004 - "In this study, the pharmacokinetics of a benzoporphyrin derivative (BPD), delivered in verteporfin for injection formulation, have been quantified in the rat Dunning prostate tumor MAT-LyLu model, using both subcutaneous and orthotopic sites" 08/01/2008 - "Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy." 11/18/2006 - "Intracellular localization and concentration as well as photodynamic effects of benzoporphyrin derivative monoacid ring A in four types of rodent tumor cells." 09/01/2006 - "Tumor vascular area correlates with photosensitizer uptake: analysis of verteporfin microvascular delivery in the Dunning rat prostate tumor." Get all the results and reference details, order at left...
5.	Angioid Streaks 09/01/2002 - "Further studies with longer follow up are necessary to confirm whether verteporfin therapy is beneficial for subfoveal choroidal neovascularization related to angioid streaks." 01/01/2003 - "CONCLUSIONS: Verteporfin for choroidal neovascularization-associated with angioid streaks does not appear to significantly alter the course of this disease with most eyes undergoing enlargement and disciform transformation of the neovascular process" 07/01/2005 - "CONCLUSIONS: This small series suggests that treatment of CNV secondary to angioid streaks with verteporfin PDT seems to limit visual loss in most patients through the first 12 months of follow-up, particularly in those with subfoveal lesions at baseline." 01/01/2003 - "PURPOSE: To evaluate the efficacy of photodynamic therapy with verteporfin in the management of choroidal neovascularization (CNV) associated with angioid streaks" 09/01/2002 - "PURPOSE: To evaluate safety and efficacy of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization associated with angioid streaks" Get all the results and reference details, order at left...
109 Diseases and 492 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	1-phenyl-3,3-dimethyltriazene (PDT)
2.	verteporfin (Visudyne)
3.	ranibizumab (Lucentis)
4.	Triamcinolone Acetonide (Azmacort)
5.	Retinaldehyde (Retinal)
6.	Fluorescein (Funduscein)
7.	Liposomes (Liposome)
8.	bevacizumab
9.	Triamcinolone (Aristocort)
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
85 Drugs and Important Bio-Agents and 344 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Lasers (Laser)
3.	Induced Hyperthermia (Thermotherapy)
4.	Filtering Surgery
5.	Light Coagulation
19 Therapies and Procedures and 383 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>